Bayer (BAYRY)
(Delayed Data from OTC)
$7.34 USD
+0.26 (3.60%)
Updated Apr 22, 2024 11:55 AM ET
4-Sell of 5 4
B Value A Growth D Momentum B VGM
Company Summary
Headquartered in Leverkusen, Germany, Bayer AG is a life science company with core competencies in the areas of health care and agriculture.
With the company’s focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016.
In 2017, Bayer took a step toward its goal of achieving complete separation from Covestro in the medium term by selling about 36% of the interest in that company for €4.7 billion. Bayer ceded de facto control of Covestro and deconsolidated the company at the end of September 2017.
The company ...
Company Summary
Headquartered in Leverkusen, Germany, Bayer AG is a life science company with core competencies in the areas of health care and agriculture.
With the company’s focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016.
In 2017, Bayer took a step toward its goal of achieving complete separation from Covestro in the medium term by selling about 36% of the interest in that company for €4.7 billion. Bayer ceded de facto control of Covestro and deconsolidated the company at the end of September 2017.
The company is now primarily focused on four core therapeutic areas — cardiovascular diseases, oncology, immunology and neurology & rare diseases.
The Crop Science Division focuses on developing, producing and marketing a broad portfolio of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture.
Pharmaceuticals business focuses on oncology, cardiovascular (including cardiovascular precision medicine, nephrology and acute care), neurology & rare diseases and immunology as therapeutic areas with high potential in terms of impact and value. The Consumer Health business focuses on developing, producing and marketing mainly nonprescription (OTC, i.e. over the counter) products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, pain and cardiovascular risk prevention categories.
Bayer recently acquired the exclusive marketing rights for cardiovascular candidate acoramidis in Europe from BridgeBio. The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.
Bayer generated revenues of €47.6 billion in 2023 compared with €50.7 billion in 2022.
General Information
Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
Leverkusen, 2M 51368
Phone: 49-21-4-30-1
Fax: 49-21-4306-6328
Web: http://www.bayer.com
Email: peter.dahlhoff@bayer.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/9/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | NA |
Current Year EPS Consensus Estimate | 1.36 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/9/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 7.08 |
52 Week High | 16.81 |
52 Week Low | 6.96 |
Beta | 1.13 |
20 Day Moving Average | 2,586,653.50 |
Target Price Consensus | 7.60 |
4 Week | -1.67 |
12 Week | -19.45 |
YTD | -23.29 |
4 Week | 3.62 |
12 Week | -20.69 |
YTD | -26.34 |
Shares Outstanding (millions) | NA |
Market Capitalization (millions) | NA |
Short Ratio | NA |
Last Split Date | 9/20/2017 |
Dividend Yield | 6.37% |
Annual Dividend | $0.45 |
Payout Ratio | 0.26 |
Change in Payout Ratio | 0.01 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 5.21 |
Trailing 12 Months | 4.12 |
PEG Ratio | NA |
vs. Previous Year | 47.06% |
vs. Previous Quarter | 400.00% |
vs. Previous Year | 4.24% |
vs. Previous Quarter | 13.48% |
Price/Book | 0.68 |
Price/Cash Flow | 1.85 |
Price / Sales | NA |
3/31/24 | NA |
12/31/23 | 17.27 |
9/30/23 | 15.24 |
3/31/24 | NA |
12/31/23 | 5.20 |
9/30/23 | 4.69 |
3/31/24 | NA |
12/31/23 | 1.27 |
9/30/23 | 1.13 |
3/31/24 | NA |
12/31/23 | 0.80 |
9/30/23 | 0.71 |
3/31/24 | NA |
12/31/23 | 13.15 |
9/30/23 | 12.11 |
3/31/24 | NA |
12/31/23 | -6.31 |
9/30/23 | -7.98 |
3/31/24 | NA |
12/31/23 | -3.40 |
9/30/23 | -5.69 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 1.43 |
9/30/23 | 1.44 |
3/31/24 | NA |
12/31/23 | 1.15 |
9/30/23 | 1.05 |
3/31/24 | NA |
12/31/23 | 53.58 |
9/30/23 | 51.14 |